Oxcia develops breakthrough drugs using DNA Damage Response, with the aim to cure cancer and inflammation. The lead compound, OXC-101, fights cancer with a first-in-class novel treatment, killing cancer cells whilst sparing the healthy cells. The second most advanced project, OXC-201, introduces a unique way to block the onset of inflammation and fibrosis.

Oxcia is seeking private investors to build Oxcia further and accelerate our drug product development. Oxcia has long term goals and the strategy is to build an innovative pharmaceutical company through cutting-edge science. It is an exciting journey to join.



Ulrika Warpman Berglund

CEO, Member of the Board

Jan Zetterberg

Jan Zetterberg

Chairman of the Board